1. A stable parenteral dosage form containing at least one dopamine agonist and a pharmaceutically acceptable excipient and having a pharmacokinetic profile that is characterized by:! a) Tmax from about 1 to about 90 minutes after administration of the parenteral dosage form； ! b) a plateau of the concentration of the drug in the plasma of at least 50% Cmax for a period of from about 90 to about 360 minutes. ! 2. The parenteral dosage form according to claim 1, having a pharmacokinetic profile in which at least 90% of the dopamine agonist is removed from the plasma within about 240 to about 480 minutes of the indicated plateau of drug concentration. ! 3. The dosage form for parenteral administration according to claim 1, characterized in that said Tmax is from about 5 to about 90 minutes after administration of the parenteral dosage form. ! 4. The parenteral dosage form according to claim 1, having a pharmacokinetic profile in which said Tmax is from about 5 to about 90 minutes after administration of the dosage form and a post-Cmax level comprising about one second Cmax is present in said plateau from about 30 to about 150 minutes from Tmax. ! 5. The parenteral dosage form according to claim 1, having a pharmacokinetic profile in which said Tmax is from about 5 to about 90 minutes after administration of the dosage form, and a post-Cmax level comprising about one second is present in said plateau1. Стабильная лекарственная форма для парентерального введения, содержащая по меньшей мере один агонист допамина и фармацевтически приемлемый наполнитель и имеющая фармакокинетический профиль, который характеризуется: ! а) Tmax приблизительно от 1 до приблизительно 90 мин после введения лекарственной формы для парентерального введения； ! б) плато концентрации лекарственного средства в плазме по меньшей мере 50% Cmax в течение периода от приблизительно 90 до приблизительно 360 мин. ! 2. Лекарственная форма для парентерального введения по п.1, имеющая фармакокинетический п
